This free independent satellite symposium, led by expert faculty members, will provide a comprehensive review of the rationale for use of mTOR inhibitors and of the current and emerging roles of these agents in clinical practice for multiple tumor types, including solid tumors and hematologic malignancies.
This presentation was selected by the American Society of Clinical Oncology® as an independent educational activity held adjunct to the ASCO Annual Meeting. This presentation is not sponsored or endorsed by ASCO.
Program Overview
In this independent satellite symposium, expert faculty will provide a comprehensive review of the rationale for use of mTOR inhibitors and role of mTOR inhibitors in clinical practice for multiple tumor types, including solid tumors and hematologic malignancies.
Purpose
The purpose of this activity is to enhance the quality of care provided by healthcare professionals involved in the management of patients with cancer by providing them with information on recent developments with mTOR inhibitors in multiple tumor types.
Target Audience
This activity is intended for physicians, registered nurses, and other healthcare providers involved in the care of patients with cancer.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the unique mechanism of action and activity of mTOR inhibitors
- Summarize clinical data on mTOR inhibition in a variety of tumor types, including renal cell carcinoma, breast cancer, and neuroendocrine tumors of the pancreas
- Discuss current and future studies of mTOR inhibitors in hematologic malignancies, including Hodgkin's and non-Hodgkin's lymphoma
- Describe the rationale for combining mTOR inhibitors with other systemic treatment agents, chemotherapeutic or biologic